s Human Platelet-Derived Growth Factor Enhances Healing of Ulcers Situated on Non-Foot Sites in Diabetics. A Pilot Study

This prospective, single centre, open –label study assessed the efficacy, efficiency and tolerability of topical recombinant human platelet –derived growth factor (rhPDGF) in the treatment of chronic ulcers at sites other than the foot in 4 patients with diabetes mellitus. RhPDGF gel 0.01% was applied once daily to the target ulcer in these patients. Efficacy was assessed in terms of ulcer size reduction and efficiency as time to complete healing. Safety was assessed in terms of incidence of adverse events. All ulcers healed completely, of which 2 healed within 2 weeks, 1 by 4 weeks, and 1 by 8 weeks.